By King & Wood Mallesons
King & Wood Mallesons (KWM) has advised Shenzhen-listed By-Health Co., Ltd. on the acquisition of Australian probiotic market leader Life-Space Group, for a purchase price of up to A$690 million.
Continue Reading KWM advises on By-Health’s $690m investment in Australia’s healthcare industry
By King & Wood Mallesons
King & Wood Mallesons (KWM) has advised Shenzhen-listed By-Health Co., Ltd. on the acquisition of Australian probiotic market leader Life-Space Group, for a purchase price of up to AU$690 million.
The transaction represents By-Health’s first major outbound acquisition in the Australian healthcare industry, with Life-Space operating the Evolution Health and Ultramix businesses as well as the Life-Space brand of probiotics.
Continue Reading KWM advises on By-Health’s AU$690m investment in Australia’s healthcare industry
By Huang Jianwen King & Wood Mallesons’ Commercial & Regulatory Group
O
n 6 June 2016, 7 months after the China Food and Drug Administration (“CFDA”) published the Pilot Plan for the Drug Marketing Authorization Holder Mechanism (Draft for Public Opinions) (“Draft for Public Opinions”), the General Office of the State
By Li Qiang King & Wood Mallesons’ Corporate & Securities Group
I
n recent years, the Chinese government has been dedicated to the reform of state-owned hospitals and has issued a series of policy papers in this field, including Opinions of the State Council on Deepening Medicine and Health System Reform issued by the State
By Huang Jianwen King & Wood Mallesons’ Commercial & Regulatory Group
We have analyzed drug policies with regard to drug pricing and the centralized procurement of drugs in the previous Key 2015 Healthcare and Pharmaceutical Policies: Pharmaceuticals. This article will sort out China’s key regulations and policies in 2015 related to healthcare from five aspects
By Huang Jianwen King and Wood Mallesons’ Commercial & Regulatory Group
Along with the rapid development of the healthcare and pharmaceutical industry, various key policies have been published recently. This article will sort out China’s key regulations and policies in 2015 related to drugs from three aspects – drug prices, drug evaluations, and drug procurements.
By King & Wood Mallesons’ Healthcare Group
China’s National Health and Family Planning Commission(” NHFPC “) has recently stepped up its efforts to strengthen the administration of healthcare industry with a serial of regulations and actions, with a focus to crack down on and actions, with a focus to crack down on commercial bribery and illegal medical practice.
Continue Reading China’s NHFPC Further Strengthening its Scrutiny over Irregularities in the Healthcare Industry
By King & Wood Mallesons’ Healthcare Group
On 13 November 2013, Shanghai Municipality released the Provisional Measures on the Administration of Wholly Foreign-Owned Medical Institutions in the China (Shanghai) Pilot Free Trade Zone (hufubanfa [2013] No.63, “Measures”), which provides the requirements and application matters for foreign investors to set up medical institutions in the form of wholly foreign-owned enterprises (“WFOE Medical Institution(s)”) in China (Shanghai) Pilot Free Trade Zone (“FTZ”) with the highlights as follows:
Continue Reading Shanghai Municipality Released the Provisional Measures on the Administration of Wholly Foreign-Owned Medical Institutions in the China (Shanghai) Pilot Free Trade Zone
